表紙：後天性希少血液疾患の世界市場：北米が世界市場の3分の1を超えるシェアを獲得

市場調査レポート

商品コード

1181062

後天性希少血液疾患の世界市場：北米が世界市場の3分の1を超えるシェアを獲得

Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share

出版日: 2022年10月04日 | 発行: Persistence Market Research

| ページ情報: 英文 250 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 4,900 768,124円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピーはできません。PDFの印刷もできません。

PDF (Multi User License)

USD 7,600 1,191,376円

レポートPDFを同一企業内の5名様までご利用頂けるライセンスです。PDF内のテキストの編集が可能です。PDFの印刷は5部までとし、そのご利用はPDFのご利用範囲に準拠します。

PDF (Corporate User License)

USD 10,600 1,661,656円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキストの編集が可能です。印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の後天性希少血液疾患市場を調査し、市場の概要や動向、成功要因、市場の背景、セグメント別・地域別の市場分析と予測、競合情勢などをまとめています。

マクロ経済要因
- 世界のGDP成長の見通し
- 世界の業界付加価値の概要
- 世界のインフラ投資の概要
- 世界の建設支出分析
- その他のマクロ経済要因
予測要因：関連性と影響
- トップ企業の歴史的成長
- GDP成長予測
- 建設業界の予測
- 流通チャネルの成長見通し
- コラボレーション活動
バリューチェーン
- 原材料サプライヤー
- メーカーリスト
- 代理店リスト
COVID-19危機：影響評価
- 現在の統計
- 短中長期の見通し
- 回復の可能性
市場力学
- 促進要因
- 抑制要因
- 機会分析
- 動向

第9章世界の後天性希少血液疾患市場の分析と予測：治療別

イントロダクション/主な調査結果
過去の市場と数量の分析：治療別
現在および将来の市場と数量の分析と予測：治療別
- 組み換え因子
- 免疫グロブリン注入療法
- 活性型プロトロンビン複合体製剤
- トロンボポエチン受容体作動薬
- その他
市場の魅力度分析：治療別

第10章世界の後天性希少血液疾患市場の分析と予測：適応症別

イントロダクション/主な調査結果
過去の市場と数量の分析：適応症別
現在および将来の市場と数量の分析と予測：適応症別
- 後天性無顆粒球症
- 後天性血友病
- 後天性フォンヴィレブランド病
- 発作性夜間ヘモグロビン尿症（PNH）
- 骨髄異形成症候群
- その他
市場の魅力度分析：適応症別

第11章世界の後天性希少血液疾患市場の分析と予測：流通チャネル別

イントロダクション/主な調査結果
過去の市場と数量の分析：流通チャネル別
現在および将来の市場と数量の分析と予測：流通チャネル別
- 病院薬局
- 小売薬局
- その他
市場の魅力度分析：流通チャネル別

第12章世界の後天性希少血液疾患市場の分析と予測：地域別

イントロダクション
過去の市場と数量の分析：地域別
現在の市場と数量の分析と予測：地域別
- 北米
- ラテンアメリカ
- 欧州
- 東アジア
- 南アジア・太平洋地域
- 中東・アフリカ
市場の魅力度分析：地域別

第13章北米の後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第14章ラテンアメリカの後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第15章欧州の後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第16章南アジア・太平洋地域の後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第17章東アジアの後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第18章中東・アフリカの後天性希少血液疾患市場の分析と予測

イントロダクション
価格分析
過去の市場と数量の動向分析：市場分類別
市場と数量の予測：市場分類別
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場の魅力度分析
- 国別
- タイプ別
- 適応症別
- 流通チャネル別
市場動向
主要な市場参入企業：強度マッピング
促進要因と抑制要因：影響分析

第19章新興国の後天性希少血液疾患市場の分析と予測

イントロダクション
- 市場価値比率分析：主要国別
- 世界/国の成長比較
米国の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
カナダの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
メキシコの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
ブラジルの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
ドイツの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
イタリアの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
フランスの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
英国の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
スペインの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
ベネルクスの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
ロシアの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
中国の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
日本の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
韓国の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
インドの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
ASEANの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
オーストラリア・ニュージーランドの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
GCC諸国の後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
トルコの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
北アフリカの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別
南アフリカの後天性希少血液疾患市場の分析
- タイプ別
- 適応症別
- 流通チャネル別

第20章市場構造分析

市場分析：企業階層別
主要企業の市場シェア分析
市場プレゼンス分析

第21章競合分析

競合ダッシュボード
競合のベンチマーク
競合の詳細
- Alexion Pharmaceuticals, Inc.
- Amgen, Inc.
- Celgene Corporation
- Eli Lilly and Company
- Sanofi S.A.
- GlaxoSmithKline plc.
- Cyclacel Pharmaceuticals, Inc.
- Onconova Therapeutics, Inc.
- Incyte Corporation
- CTI BioPharma Corp.

第22章前提と使用した頭字語

第23章調査手法

図表

List of Tables

Table 01: Global Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 02: Global Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 03: Global Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 04: Global Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Region, 2017- 2032
Table 05: North America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
Table 06: North America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 07: North America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 08: North America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 09: Latin America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
Table 10: Latin America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 11: Latin America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 12: Latin America Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 13: Europe Acquired Orphan Blood Disease Market Volume ('000 Units) Forecast by Country 2017- 2032
Table 14: Europe Acquired Orphan Blood Disease Market Value(US $ Mn) Forecast by Country, 2017- 2032
Table 15: Europe Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 16: Europe Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 17: Europe Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 18: South Asia & Pacific Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country,2017- 2032
Table 19: South Asia & Pacific Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 20: South Asia & Pacific Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 21: South Asia & Pacific Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 22: East Asia Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017- 2032
Table 23: East Asia Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 24: East Asia Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 25: East Asia Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032
Table 26: Middle East & Africa Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country, 2017- 2032
Table 27: Middle East & Africa Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Therapy, 2017- 2032
Table 28: Middle East & Africa Acquired Orphan Blood Disease Market Volume ('000 Units) & Value (US$ Mn) Forecast by Disease Indication, 2017- 2032
Table 29: Middle East & Africa Acquired Orphan Blood Disease Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017- 2032

List of Figures

Figure 01: Global Acquired Orphan Blood Disease Market Historical Volume ('000 Units), 2017 - 2021
Figure 02: Global Acquired Orphan Blood Disease Market Volume ('000 Units) Forecast, 2022 - 2032
Figure 03: Global Acquired Orphan Blood Disease Market Size (2017-2021)
Figure 04: Global Acquired Orphan Blood Disease Absolute $ Opportunity Analysis (2017-2032)
Figure 05: Global Acquired Orphan Blood Disease Market Size (2022-2032)
Figure 06: Global Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 07: Global Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 08: Global Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 09: Global Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 10: Global Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 11: Global Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 12: Global Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 13: Global Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 14: Global Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 15: Global Acquired Orphan Blood Disease Market BPS Analysis by Region- 2022 & 2032
Figure 16: Global Acquired Orphan Blood Disease Market Y-o-Y Growth by Region, 2021- 2032
Figure 17: Global Acquired Orphan Blood Disease Market Attractiveness Analysis by Region, 2022- 2032
Figure 18: North America Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 19: North America Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 20: North America Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 21: North America Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 22: North America Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 23: North America Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 24: North America Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 25: North America Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 26: North America Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 27: North America Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 28: North America Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 29: North America Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 30: Latin America Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 31: Latin America Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 32: Latin America Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 33: Latin America Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 34: Latin America Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 35: Latin America Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 36: Latin America Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 37: Latin America Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 38: Latin America Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 39: Latin America Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 40: Latin America Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 41: Latin America Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 42: Europe Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 43: Europe Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 44: Europe Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 45: Europe Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 46: Europe Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 47: Europe Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 48: Europe Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 49: Europe Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 50: Europe Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 51: Europe Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 52: Europe Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 53: Europe Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 54: South Asia & Pacific Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 55: South Asia & Pacific Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 56: South Asia & Pacific Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 57: South Asia & Pacific Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 58: South Asia & Pacific Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 59: South Asia & Pacific Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 60: South Asia & Pacific Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 61: South Asia & Pacific Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 62: South Asia & Pacific Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 63: South Asia & Pacific Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 64: South Asia & Pacific Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 65: South Asia & Pacific Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 66: East Asia Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 67: East Asia Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 68: East Asia Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 69: East Asia Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 70: East Asia Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 71: East Asia Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 72: East Asia Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 73: East Asia Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 74: East Asia Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 75: East Asia Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 76: East Asia Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 77: East Asia Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032
Figure 78: Middle East & Africa Acquired Orphan Blood Disease Market BPS Analysis by Country- 2022 & 2032
Figure 79: Middle East & Africa Acquired Orphan Blood Disease Market Y-o-Y Growth by Country, 2021- 2032
Figure 80: Middle East & Africa Acquired Orphan Blood Disease Market Attractiveness Analysis by Country, 2022- 2032
Figure 81: Middle East & Africa Acquired Orphan Blood Disease Market BPS Analysis by Therapy- 2022 & 2032
Figure 82: Middle East & Africa Acquired Orphan Blood Disease Market Y-o-Y Growth by Therapy, 2021- 2032
Figure 83: Middle East & Africa Acquired Orphan Blood Disease Market Attractiveness Analysis by Therapy, 2022- 2032
Figure 84: Middle East & Africa Acquired Orphan Blood Disease Market BPS Analysis by Disease Indication- 2022 & 2032
Figure 85: Middle East & Africa Acquired Orphan Blood Disease Market Y-o-Y Growth by Disease Indication, 2021- 2032
Figure 86: Middle East & Africa Acquired Orphan Blood Disease Market Attractiveness Analysis by Disease Indication, 2022- 2032
Figure 87: Middle East & Africa Acquired Orphan Blood Disease Market BPS Analysis by Distribution Channel- 2022 & 2032
Figure 88: Middle East & Africa Acquired Orphan Blood Disease Market Y-o-Y Growth by Distribution Channel, 2021- 2032
Figure 89: Middle East & Africa Acquired Orphan Blood Disease Market Attractiveness Analysis by Distribution Channel, 2022- 2032

Product Code: PMRREP4464

Report Scope:

The latest market report by Persistence Market Research on the global acquired orphan blood disease market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides a detailed assessment of key market dynamics and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with an acquired orphan blood disease. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to the compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on future trends in the market. Furthermore, new and emerging players in the global acquired orphan blood disease market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the acquired orphan blood disease market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research's report on the global acquired orphan blood disease market offers information divided into four segments - therapy, disease indication, distribution channel, and region.

Therapy

Recombinant Factor

Immunoglobulin Infusion Therapy

Activated Prothrombin Complex Concentrate

Thrombopoietin Receptor Agonists

Others

Disease Indication

Acquired Agranulocytosis

Acquired Hemophilia

Acquired Von Willebrand Syndrome

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Myelodysplastic Syndrome

Other

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Region

North America

Europe

Latin America

East Asia

The Middle East & Africa

South Asia & Pacific

Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?

Which region is experiencing the highest growth (CAGR)?

Which factors are impacting the global acquired orphan blood disease industry?

What are the global trends impacting the market?

What strategies must emerge players adopt to capture opportunities in various regions in the market?

What is the structure of the global acquired orphan blood disease market?

Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global acquired orphan blood disease market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions - North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research

Secondary Research

Trade Research

Social Media Research

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Strategic Promotional Strategies

5. Global Acquired Orphan Blood Disease Market Demand Analysis 2017-2021 and Forecast, 2022-2032

5.1. Historical Market Volume (Tons) Analysis, 2017-2021
5.2. Current and Future Market Volume (Tons) Projections, 2022-2032
5.3. Y-o-Y Growth Trend Analysis

6. Global Acquired Orphan Blood Disease Market - Pricing Analysis

6.1. Regional Pricing Analysis By Therapy
6.2. Global Average Pricing Analysis Benchmark

7. Global Acquired Orphan Blood Disease Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

8.1. Macro-Economic Factors
- 8.1.1. Global GDP Growth Outlook
- 8.1.2. Global Industry Value Added Overview
- 8.1.3. Global Infrastructure Investment Overview
- 8.1.4. Global Construction Spending Analysis
- 8.1.5. Other Macro Economic Factors
8.2. Forecast Factors - Relevance & Impact
- 8.2.1. Top Companies Historical Growth
- 8.2.2. GDP Growth forecast
- 8.2.3. Construction Industry forecast
- 8.2.4. Distribution Channel Growth Outlook
- 8.2.5. Collaboration Activities
8.3. Value Chain
- 8.3.1. Raw Material Suppliers
- 8.3.2. List of Manufacturers
- 8.3.3. List of Distributors
8.4. COVID-19 Crisis - Impact Assessment
- 8.4.1. Current Statistics
- 8.4.2. Short-Mid-Long Term Outlook
- 8.4.3. Likely Rebound
8.5. Market Dynamics
- 8.5.1. Drivers
- 8.5.2. Restraints
- 8.5.3. Opportunity Analysis
- 8.5.4. Trends

9. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, by Therapy

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017-2021
9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Therapy 2022-2032
- 9.3.1. Recombinant Factor
- 9.3.2. Immunoglobulin Infusion Therapy
- 9.3.3. Activated Prothrombin Complex Concentrate
- 9.3.4. Thrombopoietin Receptor Agonists
- 9.3.5. Others
9.4. Market Attractiveness Analysis by Therapy

10. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis By Disease Indication, 2017-2021
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Disease Indication, 2022-2032
- 10.3.1. Acquired Agranulocytosis
- 10.3.2. Acquired Hemophilia
- 10.3.3. Acquired Von Willebrand Syndrome
- 10.3.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 10.3.5. Myelodysplastic Syndrome
- 10.3.6. Others
10.4. Market Attractiveness Analysis By Disease Indication

11. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017-2021
11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022-2032
- 11.3.1. Hospital Pharmacy
- 11.3.2. Retail Pharmacy
- 11.3.3. Others
11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, by Region

12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017-2021
12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022-2032
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia and Pacific
- 12.3.6. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region

13. North America Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 13.4.1. By Country
  - 13.4.1.1. U.S.
  - 13.4.1.2. Canada
- 13.4.2. By Type
- 13.4.3. By Disease Indication
- 13.4.4. By Distribution Channel
13.5. Market Attractiveness Analysis
- 13.5.1. By Country
- 13.5.2. By Type
- 13.5.3. By Disease Indication
- 13.5.4. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis

14. Latin America Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 14.4.1. By Country
  - 14.4.1.1. Brazil
  - 14.4.1.2. Mexico
  - 14.4.1.3. Rest of Latin America
- 14.4.2. By Type
- 14.4.3. By Disease Indication
- 14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
- 14.5.1. By Country
- 14.5.2. By Type
- 14.5.3. By Disease Indication
- 14.5.4. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis

15. Europe Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 15.4.1. By Country
  - 15.4.1.1. Germany
  - 15.4.1.2. Italy
  - 15.4.1.3. France
  - 15.4.1.4. U.K.
  - 15.4.1.5. Spain
  - 15.4.1.6. BENELUX
  - 15.4.1.7. Russia
  - 15.4.1.8. Rest of Europe
- 15.4.2. By Type
- 15.4.3. By Disease Indication
- 15.4.4. By Distribution Channel
15.5. Market Attractiveness Analysis
- 15.5.1. By Country
- 15.5.2. By Type
- 15.5.3. By Disease Indication
- 15.5.4. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 16.4.1. By Country
  - 16.4.1.1. India
  - 16.4.1.2. ASEAN
  - 16.4.1.3. Oceania
  - 16.4.1.4. Rest of South Asia & Pacific
- 16.4.2. By Type
- 16.4.3. By Disease Indication
- 16.4.4. By Distribution Channel
16.5. Market Attractiveness Analysis
- 16.5.1. By Country
- 16.5.2. By Type
- 16.5.3. By Disease Indication
- 16.5.4. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis

17. East Asia Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 17.4.1. By Country
  - 17.4.1.1. China
  - 17.4.1.2. Japan
  - 17.4.1.3. South Korea
- 17.4.2. By Type
- 17.4.3. By Disease Indication
- 17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
- 17.5.1. By Country
- 17.5.2. By Type
- 17.5.3. By Disease Indication
- 17.5.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
- 18.4.1. By Country
  - 18.4.1.1. GCC Countries
  - 18.4.1.2. Turkey
  - 18.4.1.3. Northern Africa
  - 18.4.1.4. South Africa
  - 18.4.1.5. Rest of Middle East and Africa
- 18.4.2. By Type
- 18.4.3. By Disease Indication
- 18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
- 18.5.1. By Country
- 18.5.2. By Type
- 18.5.3. By Disease Indication
- 18.5.4. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Acquired Orphan Blood Disease Market Analysis

19.1. Introduction
- 19.1.1. Market Value Proportion Analysis, By Key Countries
- 19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Acquired Orphan Blood Disease Market Analysis
- 19.2.1. By Type
- 19.2.2. By Disease Indication
- 19.2.3. By Distribution Channel
19.3. Canada Acquired Orphan Blood Disease Market Analysis
- 19.3.1. By Type
- 19.3.2. By Disease Indication
- 19.3.3. By Distribution Channel
19.4. Mexico Acquired Orphan Blood Disease Market Analysis
- 19.4.1. By Type
- 19.4.2. By Disease Indication
- 19.4.3. By Distribution Channel
19.5. Brazil Acquired Orphan Blood Disease Market Analysis
- 19.5.1. By Type
- 19.5.2. By Disease Indication
- 19.5.3. By Distribution Channel
19.6. Germany Acquired Orphan Blood Disease Market Analysis
- 19.6.1. By Type
- 19.6.2. By Disease Indication
- 19.6.3. By Distribution Channel
19.7. Italy Acquired Orphan Blood Disease Market Analysis
- 19.7.1. By Type
- 19.7.2. By Disease Indication
- 19.7.3. By Distribution Channel
19.8. France Acquired Orphan Blood Disease Market Analysis
- 19.8.1. By Type
- 19.8.2. By Disease Indication
- 19.8.3. By Distribution Channel
19.9. U.K. Acquired Orphan Blood Disease Market Analysis
- 19.9.1. By Type
- 19.9.2. By Disease Indication
- 19.9.3. By Distribution Channel
19.10. Spain Acquired Orphan Blood Disease Market Analysis
- 19.10.1. By Type
- 19.10.2. By Disease Indication
- 19.10.3. By Distribution Channel
19.11. BENELUX Acquired Orphan Blood Disease Market Analysis
- 19.11.1. By Type
- 19.11.2. By Disease Indication
- 19.11.3. By Distribution Channel
19.12. Russia Acquired Orphan Blood Disease Market Analysis
- 19.12.1. By Type
- 19.12.2. By Disease Indication
- 19.12.3. By Distribution Channel
19.13. China Acquired Orphan Blood Disease Market Analysis
- 19.13.1. By Type
- 19.13.2. By Disease Indication
- 19.13.3. By Distribution Channel
19.14. Japan Acquired Orphan Blood Disease Market Analysis
- 19.14.1. By Type
- 19.14.2. By Disease Indication
- 19.14.3. By Distribution Channel
19.15. S. Korea Acquired Orphan Blood Disease Market Analysis
- 19.15.1. By Type
- 19.15.2. By Disease Indication
- 19.15.3. By Distribution Channel
19.16. India Acquired Orphan Blood Disease Market Analysis
- 19.16.1. By Type
- 19.16.2. By Disease Indication
- 19.16.3. By Distribution Channel
19.17. ASEAN Acquired Orphan Blood Disease Market Analysis
- 19.17.1. By Type
- 19.17.2. By Disease Indication
- 19.17.3. By Distribution Channel
19.18. Australia and New Zealand Acquired Orphan Blood Disease Market Analysis
- 19.18.1. By Type
- 19.18.2. By Disease Indication
- 19.18.3. By Distribution Channel
19.19. GCC Countries Acquired Orphan Blood Disease Market Analysis
- 19.19.1. By Type
- 19.19.2. By Disease Indication
- 19.19.3. By Distribution Channel
19.20. Turkey Acquired Orphan Blood Disease Market Analysis
- 19.20.1. By Type
- 19.20.2. By Disease Indication
- 19.20.3. By Distribution Channel
19.21. Northern Africa Acquired Orphan Blood Disease Market Analysis
- 19.21.1. By Type
- 19.21.2. By Disease Indication
- 19.21.3. By Distribution Channel
19.22. South Africa Acquired Orphan Blood Disease Market Analysis
- 19.22.1. By Type
- 19.22.2. By Disease Indication
- 19.22.3. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. Alexion Pharmaceuticals, Inc.
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.1.4. Sales Footprint
  - 21.3.1.5. Strategy Overview
- 21.3.2. Amgen, Inc.
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.2.4. Sales Footprint
  - 21.3.2.5. Strategy Overview
- 21.3.3. Celgene Corporation
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.3.4. Sales Footprint
  - 21.3.3.5. Strategy Overview
- 21.3.4. Eli Lilly and Company
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.4.4. Sales Footprint
  - 21.3.4.5. Strategy Overview
- 21.3.5. Sanofi S.A.
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.5.4. Sales Footprint
  - 21.3.5.5. Strategy Overview
- 21.3.6. GlaxoSmithKline plc.
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.6.4. Sales Footprint
  - 21.3.6.5. Strategy Overview
- 21.3.7. Cyclacel Pharmaceuticals, Inc.
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.7.4. Sales Footprint
  - 21.3.7.5. Strategy Overview
- 21.3.8. Onconova Therapeutics, Inc.
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.8.4. Sales Footprint
  - 21.3.8.5. Strategy Overview
- 21.3.9. Incyte Corporation
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.9.4. Sales Footprint
  - 21.3.9.5. Strategy Overview
- 21.3.10. CTI BioPharma Corp.
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
  - 21.3.10.4. Sales Footprint
  - 21.3.10.5. Strategy Overview

後天性希少血液疾患の世界市場：北米が世界市場の3分の1を超えるシェアを獲得

Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要な市場動向

第4章 主な成功要因

第5章 世界の後天性希少血液疾患市場の需要分析と予測

第6章 世界の後天性希少血液疾患市場：価格分析

第7章 世界の後天性希少血液疾患市場の需要（金額/規模）の分析と予測

第8章 市場の背景

第9章 世界の後天性希少血液疾患市場の分析と予測：治療別

第10章 世界の後天性希少血液疾患市場の分析と予測：適応症別

第11章 世界の後天性希少血液疾患市場の分析と予測：流通チャネル別

第12章 世界の後天性希少血液疾患市場の分析と予測：地域別

第13章 北米の後天性希少血液疾患市場の分析と予測

第14章 ラテンアメリカの後天性希少血液疾患市場の分析と予測

第15章 欧州の後天性希少血液疾患市場の分析と予測

第16章 南アジア・太平洋地域の後天性希少血液疾患市場の分析と予測

第17章 東アジアの後天性希少血液疾患市場の分析と予測

第18章 中東・アフリカの後天性希少血液疾患市場の分析と予測

第19章 新興国の後天性希少血液疾患市場の分析と予測

第20章 市場構造分析

第21章 競合分析

第22章 前提と使用した頭字語

第23章 調査手法